<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 Protein (PARK9)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP13A2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP13A2 (PARK9)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATP13A2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">181 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 Protein (PARK9)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP13A2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP13A2 (PARK9)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATP13A2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">181 edges</a></td>
</tr>
</table>
ATP13A2 is a member of the P-type ATPase family that functions as a lysosomal cation transporter, primarily pumping manganese and other cations across the lysosomal membrane[@ramirez2006]. The gene encoding ATP13A2 (also known as PARK9) was first linked to Parkinson's disease through identification of mutations causing Kufor-Rakeb syndrome (KRS), a rare form of early-onset parkinsonism with additional neurological features including dementia and supranuclear gaze palsy[@williams2005]. ATP13A2 dysfunction leads to lysosomal metal ion dysregulation, impaired autophagy, and increased sensitivity to manganese toxicity, all of which contribute to neurodegeneration[@schneider2010].
The discovery of ATP13A2 mutations in PARK9 expanded understanding of the genetic basis of Parkinson's disease and revealed new insights into lysosomal function as a critical pathway in neuronal survival[@zhang2018]. Research has demonstrated that ATP13A2 deficiency leads to impaired lysosomal degradative capacity, accumulation of autophagic vacuoles, and eventual neuronal death, establishing lysosomal dysfunction as a key mechanism in neurodegeneration[@zhang2016].
ATP13A2 is a large transmembrane protein with 1298 amino acids, containing multiple transmembrane domains that form the channel for cation transport across the lysosomal membrane[@khlbrandt2004]. Like other P-type ATPases, ATP13A2 utilizes ATP hydrolysis to drive the active transport of cations, with specificity for manganese ions (Mn²⁺) as its primary substrate[@sorensen2000]. The protein contains characteristic motifs including the phosphorylation domain (P-domain) and ATP-binding domain (A-domain) that are essential for its enzymatic activity[@bublitz2015].
The N-terminal region of ATP13A2 contains regulatory domains that modulate its activity in response to cellular conditions, while the C-terminal tail extends into the cytosol and may participate in protein-protein interactions[@axelsen2012]. Importantly, ATP13A2 localizes primarily to lysosomes and late endosomes, where it maintains ionic homeostasis essential for normal lysosomal function[@dehay2012].
The primary physiological function of ATP13A2 is maintaining lysosomal manganese homeostasis[@gonzalezcuyar2014]. Lysosomes accumulate metals as part of cellular detoxification processes, and ATP13A2 actively pumps excess manganese into the cytosol for further processing or export[@tuschl2016]. This function is particularly important in neurons, which are highly sensitive to metal ion imbalance and rely heavily on lysosomal degradation pathways[@nixon2013].
Beyond manganese transport, ATP13A2 also transports other cations including zinc (Zn²⁺), iron (Fe²⁺), and calcium (Ca²⁺), suggesting broader roles in lysosomal ion balance[@chen2015]. The dysregulation of these ions contributes to various cellular stresses including oxidative damage, mitochondrial dysfunction, and impaired protein degradation[@jellinger2009].
Kufor-Rakeb syndrome is an autosomal recessive neurodegenerative disorder caused by homozygous or compound heterozygous mutations in the ATP13A2 gene[@behrens2010]. First described in a consanguineous family from Kuwait, the syndrome is characterized by early-onset parkinsonism (typically before age 20), progressive supranuclear gaze palsy, and cognitive decline[@almoneyai2019]. Brain imaging shows characteristic atrophy of the basal ganglia and cerebral cortex[@shin2015].
The disease-causing mutations in ATP13A2 include nonsense mutations, frameshift mutations, and missense mutations that result in truncated or dysfunctional protein products[@eiberg2012]. Most pathogenic variants lead to complete loss of ATP13A2 function, underscoring the critical importance of this protein for neuronal survival[@klein2012]. Fibroblasts from KRS patients show marked lysosomal dysfunction, impaired autophagy, and increased sensitivity to manganese-induced toxicity[@sikkema2019].
Beyond the monogenic form seen in KRS, ATP13A2 variants have been implicated in susceptibility to idiopathic Parkinson's disease[@liu2014]. Genome-wide association studies have identified single nucleotide polymorphisms in the ATP13A2 region that correlate with PD risk, though the effect sizes are modest[@nalls2014]. Additionally, reduced ATP13A2 expression has been observed in the substantia nigra of PD patients, suggesting that downregulation of this lysosomal pump may contribute to sporadic disease[@meksuriyen2018].
The link between ATP13A2 and PD is reinforced by its functional interactions with other PD-associated proteins[@burbulla2017]. Alpha-synuclein, the primary protein aggregating in PD, accumulates in lysosomes and can inhibit ATP13A2 function[@miranda2018]. Conversely, ATP13A2 deficiency promotes alpha-synuclein aggregation, creating a feedforward loop of toxicity[@bourdenx2019]. This interaction provides a mechanistic link between genetic risk factors and the hallmark pathological features of PD[@wong2018].
ATP13A2 dysfunction may also contribute to other neurodegenerative conditions characterized by lysosomal impairment[@mazzulli2016]. Studies have found altered ATP13A2 expression in Alzheimer's disease brains and in models of amyotrophic lateral sclerosis (ALS)[@hashimoto2018]. The broad role of lysosomal function in protein homeostasis suggests that ATP13A2 deficiency could exacerbate pathology in multiple neurodegenerative conditions[@fricker2019].
Gene therapy to restore ATP13A2 function represents a promising therapeutic strategy for ATP13A2-related disorders[@steger2016]. Adeno-associated virus (AAV)-mediated delivery of wild-type ATP13A2 has shown efficacy in cellular and animal models, restoring lysosomal function and reducing neurotoxicity[@zhang2020]. Current research focuses on optimizing delivery vectors and achieving sufficient expression in the human brain[@hudry2019].
High-throughput screening has identified small molecules that enhance ATP13A2 expression or activity[@matsui2015]. These compounds include transcriptional activators that upregulate ATP13A2 gene expression and direct activators that enhance the pumping activity of existing protein[@zhang2018a]. Preclinical studies show that such agents can rescue lysosomal dysfunction in cellular models of ATP13A2 deficiency[@ugunklusek2019].
Given the central role of manganese dysregulation in ATP13A2-related pathology, manganese chelation therapy has been explored as a symptomatic treatment[@klein2011]. While chelation approaches have shown some promise in cellular models, their efficacy in patients remains to be established[@kalia2015]. The challenge lies in achieving sufficient brain penetration while avoiding disruption of normal manganese homeostasis[@bowman2017].
Genetic testing for ATP13A2 mutations is available for diagnostic confirmation in suspected Kufor-Rakeb syndrome and for genetic counseling in families with known mutations[@schneider2015]. The identification of pathogenic variants confirms the diagnosis and enables predictive testing for at-risk family members[@klein2013].
Several biomarker approaches are under development for ATP13A2-related disorders[@chen2020]. These include measurement of lysosomal function in patient-derived cells, neuroimaging to assess brain atrophy patterns, and biochemical markers of oxidative stress and neuroinflammation[@parnetti2019]. While no validated clinical biomarkers exist yet, research in this area is active and may yield useful tools for disease monitoring and therapeutic trials[@mollenhauer2016].
The following diagram shows the key molecular relationships involving ATP13A2 Protein (PARK9) discovered through SciDEX knowledge graph analysis: